TRAITEMENT MEDICAMENTEUX DU DIABETE DE TYPE 2 - PART 3

Cơ sở di truyền của loại 2 bệnh tiểu đường. Curr Opin Endocrinol Diab năm 1998; 5: 116-25 38. N. C. Hales, Barker D.J.P., P. M. S. Clark, et al. Thai nhi và trẻ sơ sinh tăng trưởng và dung nạp glucose ở tuổi 64. B M J năm 1991; 303: 1019-1022 39. Garofano A., P. Czernichow, B. Bréant Suy dinh dưỡng trong tử cung phát triển của tế bào beta lẻ chuột.
Nội dung trích xuất từ tài liệu:
TRAITEMENT MEDICAMENTEUX DU DIABETE DE TYPE 2 - PART 3 TRAITEMENT MEDICAMENTEUX DU DIABETE DE TYPE 2 (ACTUALISATION) : ARGUMENTAIRE37. Elbein S.C.An update on the genetic basis of type 2 diabetes.Curr Opin Endocrinol Diab 1998 ; 5 : 116-2538. Hales C.N., Barker D.J.P., Clark P.M.S., et al.Fetal and infant growth and impaired glucose tolerance at age 64.B M J 1991 ; 303: 1019-2239. Garofano A., Czernichow P., Breant B.In utero undernutrition impairs rat beta-cell development.Diabetologia 1997 ; 40 : 1231-440. Gerich J.E.Insulin resistance is not necessarily an essential component of type 2 diabetes.J Clin Endocrinol Metab 2000 ; 85 : 2113-541. Wingard D.L., Sinsheimer P. , Barret-Connor E.L. et al.Community-based study of prevalence of NIDDM in older adults.Diabetes Care 1990 ; 13 (suppl. 2) : 3-842. Pan XR, Li GW, Hu YH et al.Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. TheDa Qing IGT and diabetes study.Diabetes Care 1997; 20: 537-4443. Tuomilheto J, Lindström J, Eriksson JG, et al.Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impairedglucose tolerance.N Engl J Med 2001; 344: 1343-5044. Diabetes Prevention Program Research Group.Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.N Engl J Med 2002; 346: 393-40345. Kahn BB, Flier JS.Obesity and insulin resistance.J Clin Invest 2000 ; 106 : 473-48146. Shulman G I.Cellular mechanisms of insulin resistance.J Clin Invest 2000 ; 106: 171-647. Kahn C.R.Insulin action, diabetogenes, and the cause of type II diabetes.Diabetes 1994 ;43 : 1066-1084.48. Gerich J.E.Insulin resistance is not necessarily an essential component of type 2 diabetes.J Clin Endocrinol Metab 2000 ; 85 : 2113-549. Weyer C, Bogardus C., Mott D.M.,et al.The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis oftype 2 diabetes mellitus.J. Clin. Invest. 1999 ; 104 : 787-797.50. Henriksen J, Alford F., Ward G., et al.Risk and mechanism of dexamethasone induced deterioration of glucose tolerance in non-diabetic first degree relatives of NIDDM patients.Diabetologia 1997 ; 40 : 1439-48 NOVEMBRE 2006 33 TRAITEMENT MEDICAMENTEUX DU DIABETE DE TYPE 2 (ACTUALISATION) : ARGUMENTAIRE51. Roder M.E, Schwartz R.S., Prigeon R.L., et al.Reduced pancreatic β-cell compensation to the insulin resistance of aging: impact on proinsulinand insulin levels.J Clin Endocrinol Metab 2000 ; 85 : 2275-8052. O’Rahilly S, Nugent Z., Rudenski A.S. et al.β-cell dysfunction, rather than insulin-insensitivy, is the primary defect in familial type 2 diabetes.Lancet 1986; 2 : 360-36453. Larsson H., Ahren B.Islet dysfunction in obese women with impaired glucose tolerance.Metabolism 1996 ; 45 : 502-50954. Eriksson J., Franssila-Kallunki A., Ekdtrand A. et al.Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus.N Engl J Med 1989; 321 : 337-4355. Mitrakou A., Kelly D., Mokan M. et alRole of reduced suppression of glucose production and diminished early insulin release inimpaired glucose tolerance.N Engl J Med 1992; 326 : 22-2956. Pimenta W., Korytkowski M., Mitrakov A. et al.Pancreatic beta-cell dysfunction as the primary genetic lesion of NIDDM.JAMA 1995 ; 273 : 1855-186157. Martin B.C., Warram J.H., K- A.S. et al.Role of glucose and insulin resistance in development of type 2 diabetes mellitus : results of a25- year follow-up study.Lancet 1992; 340 : 925-958. Warram J.H., Martin B.C., Krolewski A.S. et al.Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes inthe offspring of diabetic parents.Ann Intern Med 1990; 113 : 909-91559. Lillioja S., Mott D.M., Howard B.V. et al.Impaired glucose tolerance as a disorder of insulin action. N Engl J Med 1988 ; 318 : 1217-122560. Lillioja S., Mott D.M., Spraul M. et al.Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependentdiabetes mellitus : prospective studies of Pima Indians.N Engl J Med 1993; 329 : 1988-199261. Haffner S.M., Miettinen H., Gaskill S.P. et al.Decreased insulin secretion and increased insulin resistance and independently related to the 7-year risk of NIDDM in mexican-americans.Diabetes 1995 ; 44 : 1386-13915. LES ANTI-DIABETIQUES ORAUX 5.1. La metformine 5.1.1. PharmacologieLa metformine (dimethylbiguanide) est utilisée depuis 1957 comme agent anti-diabétique. Les autres biguanides (phenformine) ne sont plus commercialisés. NOVEMBRE 2006 34 TRAITEMENT MEDICAMENTEUX DU DIABETE DE TYPE 2 (ACTUALISATION) : ARGUMENTAIREL’absorption ...